Simple upgrade programs to our latest technology

PROGRAMS TERMS AND CONDITIONS:

• Any pump shipped between 11/14/18 and 4/11/19 is eligible to receive a Lift Ticket.
• Lift Ticket can only be redeemed once during your Replacement warranty period. A Lift Ticket cannot be redeemed if less than six (6) months remains on your pump warranty period.
• A $99 payment will be required upfront to use Lift Ticket. The Lift Ticket Program price includes one (1) insulin pump. CGM products and consumables are not included. Customer that purchased the Medtronic Access Pass are not required to pay $99 to initiate their Lift Ticket.
• After you have requested to use your Lift Ticket, it could take up to 60 days to process your order. The Lift Ticket Program does not guarantee prioritization of your order.
• The Lift Ticket Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a pump through this program.
• MiniMed™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new pump, as it could affect ongoing coverage of their future pump supplies.
• Customers must return their old pump within 30 days. Customers who do not return their pump will be charged $3,200.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged pump, the price of the new pump, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available information any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to purchase a new pump. Other restrictions may apply.
• Pricing, terms, and conditions are subject to change at any time and without notice.

• Customers with more than six months remaining on their warranty are eligible for the Pathway Program.
• The Pump Pathway Program is for pump upgrades only.
• A $399 payment will be required upfront to utilize the Pump Pathway Program. The Program price includes one (1) insulin pump. CGM products and consumables are not included.
• The Pump Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a pump through this program.
• MiniMed™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new pump, as it could affect ongoing coverage of their future pump supplies.
• Customers must return their old pump within 30 days. Customers who do not return their pump will be charged $3,200.
• Medicare customers within the 13-month rental period on a MiniMed™ 630G or MiniMed ™ 670G can participate in this program.
• An ABN will be required to utilize the Pathway program if the Medicare customer is within a 13-month rental period and transitioning from one pump to another.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged pump, the price of the new pump, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available information any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to purchase a new pump. Other restrictions may apply.
• Pricing, terms, and conditions are subject to change at any time and without notice.

• Customers with more than six months remaining on their warranty are eligible for the Pathway Program.
• A $899 payment will be required upfront to use Switch 2 System. The Program price includes one (1) insulin pump. CGM products and consumables are not included.
• Customers may receive a $400 credit for trading in a Tandem^®, Animas^®, or Roche^® pump. Customers may receive a $250 credit for trading in a Omnipod^® receiver.
• The Switch 2 System Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a pump through this program.
• MiniMed™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new pump, as it could affect ongoing coverage of their future pump supplies.
• Customers must return their old competitor pump within 30 days. Customers who do not return their pump will be charged $3,200.
• An ABN will be required to utilize the Pathway program if the Medicare customer is within a 13-month rental period and transitioning from one pump to another.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged pump, the price of the new pump, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available information any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to purchase a new pump. Other restrictions may apply.
• Pricing, terms, and conditions are subject to change at any time and without notice.

• This program is available for out-of-warranty MiniMed™ insulin pump customers as well as out-of-warranty competitor pump customers.
• A sales credit may be applied to orders where a customer is upgrading from an older model pump to a newer model pump through insurance.
• Customers may receive a $500 credit for trading in a MiniMed™ , Tandem^®, Animas^®, or Roche^® pump. Customers may receive a $250 credit for trading in a Omnipod^® receiver.
• Customers must return their old pump within 30 days. Failure to return your old pump will disqualify you for the Pump Trade-in Program credit, and you will be responsible for the full estimated cost of the Medtronic pump system being purchased.
• MiniMed™ pumps sold through insurance come with a limited four (4) year warranty.
• MiniMed™ pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• A valid prescription will be required to purchase a new pump. Other restrictions may apply.
• Pricing, terms, and conditions are subject to change at any time and without notice.

• The Guardian™ Connect System Smart Step Pathway Program is for Standalone Guardian™ Connect System customers transitioning to a Medtronic sensor-augmented insulin pump system only. CGM supplies and consumables are not included.
• Customers must have an in-warranty transmitter to participate in the Guardian™ Connect System Smart Step Pathway Program.
• This program is available to customers who have insurance coverage for the Guardian™ Connect System.
• Customers transitioning from one Medtronic CGM system will not have any upfront out-of-pocket costs to Pathway to another Medtronic CGM transmitter.
• Upon completion of the transaction, customers will receive one (1) transmitter that is compatible with their current pump system.
• The Guardian™ Connect System Smart Step Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a CGM through this program.
• MiniMed™ CGM's have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new CGM, as it could affect ongoing coverage of their future CGM supplies.
• Customers must return their old CGM within 30 days. Customers who do not return their CGM will be charged $200.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged CGM, the price of the new CGM, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available information any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to obtain a new CGM. Other restrictions may apply.
• Program terms and conditions are subject to change at any time and without notice.

• This program allows MiniMed™ 770G system users a software upgrade at no charge within one year from the date of this software approval. Software approval will be announced.
• Software upgrade process is subject to change. The process may result in healthcare provider office visit and may result in out-of-pocket expenses such as co-pay, depending on insurance coverage. The process may require the completion of product related training.
• This program includes the insulin pump software only. CGM products and consumables are not included in this offer.
• Warranty dates do not reset. The replacement warranty date of an insulin pump upgraded with the software will remain the same as the replacement warranty date of the initial pump purchased. Your warranty date does not impact eligibility for a software update.
• MiniMed™ pumps and software have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your healthcare provider regarding your eligibility to receive the software upgrade based on the labeling of the upgrade, which may differ from the labeling of the MiniMed™ 770G pump.
• Insurance coverage and plan design varies and may impact the ability to upgrade. Coverage is contingent upon your health insurance medical policy guidelines. Restrictions and medical necessity requirements may apply.
• A valid prescription will be required for this software upgrade. All participants should consult their healthcare provider for all therapy related decisions.
• Program terms and conditions are subject to change at any time and without notice. Other restrictions may apply.

• The Continuous Glucose Monitor (CGM) Pathway Program is for CGM upgrades only. CGM supplies and consumables are not included, unless otherwise stated.
• Customers must have an in-warranty transmitter to participate in the CGM Pathway Program.
• This program is available to customers whose payers bill transmitters and sensors separately. Customers whose payers utilize a monthly CGM supply allowance are excluded from this program.
• Customers transitioning from one Medtronic CGM system will not have any upfront out-of-pocket costs to Pathway to another Medtronic CGM transmitter.
• Upon completion of the transaction, customers will receive one (1) transmitter that is compatible with their current pump system.
• The CGM Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a CGM through this program.
• MiniMed™ CGM's have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new CGM, as it could affect ongoing coverage of their future CGM supplies.
• Customers must return their old transmitter within 30 days. Customers who do not return their CGM will be charged $200.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged CGM, the price of the new CGM, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available information any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to obtain a new CGM. Other restrictions may apply.
• Program terms and conditions are subject to change at any time and without notice.

• The Competitor Continuous Glucose Monitor (CGM) Pathway Program is for Competitor CGM upgrades only. CGM transmitters and sensors are included with this transaction.
• Customers must have an in-warranty transmitter to participate in the Competitor Continuous Glucose Monitor (CGM) Pathway Program.
• Customers transitioning from a Competitor CGM will pay $100 out-of-pocket to purchase a Medtronic CGM transmitter and one (1) 5-pack of sensors.
• Customers must return their old transmitter within 30 days. Customers who do not return their CGM will be charged $200.
• Upon completion of the transaction, customers will receive one (1) transmitter that is compatible with their current therapy regimen and one (1) 5-pack of sensors.
• This program is available to customers whose payers bill transmitters and sensors separately. Customers whose payers utilize a monthly CGM supply allowance are excluded from this program.
• Customers using disposable CGM systems like Freestyle Libre are not eligible for the Competitor CGM Pathway Program.
• The Competitor CGM Pathway Program does not extend the warranty period of the replaced product. The customer’s current warranty timeline will not change by purchasing a CGM through this program.
• MiniMed™ CGM's have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new CGM, as it could affect ongoing coverage of their future CGM supplies.
• Customer agrees that the amount paid to Medtronic is commercially reasonable considering the approximate value of the exchanged CGM, the price of the new CGM, and the relationship between the parties.
• Customer agrees to fully and accurately report in submissions to federal healthcare programs all discounts provided by Medtronic and, upon request by the Secretary of the U.S. Department of Health and Human Services or state agency, make available information any information that Medtronic may provide concerning the discount.
• A valid prescription will be required to obtain a new CGM. Other restrictions may apply.
• Program terms and conditions are subject to change at any time and without notice.

• The Continuous Glucose Monitor (CGM) Supply Allowance Process is for CGM upgrades only. CGM supplies are included as prescribed.
• Customers transitioning from one CGM system will not have any upfront out-of-pocket transmitter cost for the opportunity to transition to another CGM transmitter.
• Applicable out-of-pocket CGM supply costs will apply.
• Upon completion of the transaction, customers will receive one (1) transmitter that is compatible with their current pump system along with their monthly one (1) 5-pack of compatible sensors and other CGM supplies as prescribed.
• This process is available to customers whose payers utilize a monthly CGM supply allowance. Customers with insurance providers that bill transmitters and sensors separately are excluded from this process.
• MiniMed™ CGM's have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your Healthcare Provider regarding indications for use.
• Customers should verify that their insurance provider will support transitioning to the new CGM, as it could affect ongoing coverage of their future CGM supplies.
• A valid prescription will be required to obtain a new CGM. Other restrictions may apply.
• Program terms and conditions are subject to change at any time and without notice.

Important Safety Information: MiniMed^™ 770G System With SmartGuard^™ Technology
The MiniMed^™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 770G System includes SmartGuard^™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed^™ 770G System consists of the following devices: MiniMed^™ 770G Insulin Pump, the Guardian^™ Link (3) Transmitter, the Guardian^™ Sensor (3), one-press serter, the Accu-Chek^® Guide Link blood glucose meter, and the Accu-Chek^® Guide Test Strips. The system requires a prescription.

The Guardian^™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian^™ Sensor (3).

All therapy adjustments should be based on measurements obtained using the Accu-Chek^® Guide Link blood glucose meter and not on values provided by the Guardian^™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek^® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.

WARNING: Do not use the SmartGuard^™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard^™ Auto Mode.

WARNING: Do not use the MiniMed^™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed^™ 770G system.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed^™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

Important Safety Information: MiniMed^™ 670G System
The Medtronic MiniMed^™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 670G system includes SmartGuard^™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian^™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR^®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR^®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian^™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR^®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.

WARNING: Medtronic performed an evaluation of the MiniMed^™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

Important Safety Information: Guardian^™ Connect CGM System
The Guardian^™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide and important safety information.